Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.

Refining IFX doses does not facilitate sustained remission after treatment discontinuation

19 Nov 2019

A programmed treatment strategy of refining infliximab (IFX) doses based on baseline serum tumour necrosis factor α (TNF-α) falls flat in sustaining remission rate in rheumatoid arthritis patients after 1 year of IFX discontinuation, according to the results of the multicentre randomized RRRR* trial.

RRRR included 337 IFX-naïve rheumatoid arthritis patients with inadequate response to methotrexate (MTX). Of these patients, 170 were assigned to the programmed treatment group that received 3 mg/kg of IFX until week 6. After 14 weeks, the dose was adjusted based on baseline serum TNF-α levels until week 54. The remaining 167 patients were assigned to the standard treatment group that received 3 mg/kg of IFX.

Sixty-seven patients (39.4 percent) in the programmed group and 54 (32.3 percent) in the standard group achieved remission at week 54 and discontinued IFX treatment. There was no significant between-group difference in the primary endpoint of sustained remission off IFX treatment at week 106: 23.5 percent vs 21.6 percent, respectively (difference, 2.2 percent, 95 percent confidence interval [CI], −6.6 percent to 11.0 percent; p=0.631).

Baseline SDAI <26.0 emerged as a significant predictor of successfully sustained discontinuation of IFX at week 106.

The findings indicate that a programmed treatment strategy does not guarantee a favourable outcome in terms of deep remission. Researchers called for additional investigation to pinpoint the patient profile most likely to benefit from discontinuation of biological disease-modifying antirheumatic drugs.

*Remission induction by raising the dose of remicade in RA

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jan 2020
Antibiotic resistance of Helicobacter (H.) pylori has more than doubled in Europe in the past two decades, raising alarm on the gravity of the issue of growing bacterial resistance to commonly-used antibiotics, a study presented at UEG Week 2019 has shown.
02 Dec 2019
Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
3 days ago
The use of folic acid in addition to enalapril in the treatment of patients with hypertension yields a modest increase in lifetime stroke-free survival, a study has found.